Singapore, Feb. 4 -- Kyowa Kirin, a Japan-based global specialty pharmaceutical company, has announced the termination of the current rocatinlimab development and commercialisation collaboration with Amgen.

Kyowa Kirin will control the global rocatinlimab programme, including regulatory filings and future commercialisation. This business decision is the result of a strategic portfolio prioritization by Amgen.

The companies are initiating a smooth and orderly transition of the programme, with a focus on ensuring continuity for participants currently enrolled in clinical trial programmes. Amgen, who has partnered with Kyowa Kirin on numerous investigational therapies over 41 years, will continue to manufacture rocatinlimab.

Published by ...